Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Fusion Antibodies PLC (LSE:FAB): Scientific Progress Supports Recovery Interest Despite Trading Pressure

The recent annual meeting update reported weaker first-half revenue, lower gross margins and a tight cash position. Management introduced cost controls and was reviewing working-capital requirements. At the same time, preclinical antibody work produced encouraging animal-model findings, while international patent progress broadened technology protection. …

Ankur Sharma | 22 October 2026

Coiled Therapeutics PLC (LSE:COIL): Oncology Trial Progress Encourages Positive Momentum Ahead of Data

The latest interim update described progress with an improved lipid-based formulation of its lead programme and enrolment across initial dose-escalation cohorts. Management expects further safety and drug-exposure evidence before year-end. Earlier financing supported the transition into a clinical-stage business and its AIM admission. These …

Ankur Sharma | 22 October 2026

Renalytix PLC (LSE:RENX): Diagnostic Partnership and Funding Progress Lift Adoption Optimism

Recent company announcements confirmed a multi-year US diagnostics collaboration and a completed fundraising intended to support its commercial rollout. The partnership is designed to broaden access to kidney risk testing through an established clinical network. The company has also announced a planned chair transition. …

Ankur Sharma | 22 October 2026

Abingdon Health’s Growth Test: Can Diagnostic Demand Turn Into Lasting Profitability?

• Abingdon Health Plc (LSE:ABDX) is being assessed against its latest disclosed business developments and sector drivers.

Ankur Sharma | 22 October 2026

Bioventix’s Specialist Antibody Model: What Could Shape Its Next Growth Chapter?

• Bioventix Plc (LSE:BVXP) is being assessed against its latest disclosed business developments and sector drivers.

Ankur Sharma | 22 October 2026

Coiled Therapeutics: The Evidence Investors Need From an Early-Stage Biotech

• Coiled Therapeutics Plc (LSE:COIL) is being assessed against its latest disclosed business developments and sector drivers.

Ankur Sharma | 22 October 2026

Creo Medical’s Growth Guidance Raises the Stakes for Second-Half Delivery

• Creo Medical Group Plc (LSE:CREO) is being assessed against its latest disclosed business developments and sector drivers.

Ankur Sharma | 22 October 2026

IXICO Outlook: Clinical-Trial Demand and Contract Conversion in Focus

• IXICO Plc (LSE:IXI) is being assessed against its latest disclosed business developments and sector drivers.

Ankur Sharma | 22 October 2026

Physiomics Wins Fresh Drug-Modelling Work: Can Contract Momentum Build?

• Physiomics Plc (LSE:PYC) is being assessed against its latest disclosed business developments and sector drivers.

Ankur Sharma | 22 October 2026

Scancell Holdings Faces a Defining Phase as Cancer Immunotherapy Milestones Approach

• Scancell Holdings Plc (LSE:SCLP) is being assessed against its latest disclosed business developments and sector drivers.

Ankur Sharma | 22 October 2026
Support

Hi! How can we help you today?

Loading…